Risk of severe dysglycemia among diabetic patients receiving levofloxacin, ciprofloxacin, or moxifloxacin in Taiwan.

MLA

Chou, Hsu-Wen, et al. “Risk of Severe Dysglycemia among Diabetic Patients Receiving Levofloxacin, Ciprofloxacin, or Moxifloxacin in Taiwan.” Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, vol. 57, no. 7, Oct. 2013, pp. 971–80. EBSCOhost, https://doi.org/10.1093/cid/cit439.

APA

Chou, H.-W., Wang, J.-L., Chang, C.-H., Lee, J.-J., Shau, W.-Y., & Lai, M.-S. (2013). Risk of severe dysglycemia among diabetic patients receiving levofloxacin, ciprofloxacin, or moxifloxacin in Taiwan. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, 57(7), 971–980. https://doi.org/10.1093/cid/cit439

Chicago

Chou, Hsu-Wen, Jiun-Ling Wang, Chia-Hsuin Chang, Jen-Jyh Lee, Wen-Yi Shau, and Mei-Shu Lai. 2013. “Risk of Severe Dysglycemia among Diabetic Patients Receiving Levofloxacin, Ciprofloxacin, or Moxifloxacin in Taiwan.” Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America 57 (7): 971–80. doi:10.1093/cid/cit439.